In the next installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD, emphasizes a patient- and caregiver-centered approach to treatment planning—highlighting how clinical decisions...
Monitoring treatment response in myelofibrosis requires a balanced assessment of patient-reported symptoms, objective scoring tools, hematologic parameters, and spleen size. In part 1 of this Myelofibrosis...
In the final installment of the Myelofibrosis Caregiver Interview Series, Fadi Haddad, MD interviews Tim F., a caregiver from Pittsburgh, PA, about the critical role caregivers play in shared...
In the latest installment of the Myelofibrosis Caregiver Interview Series, Tim F. from Pittsburgh, PA, talks with Fadi Haddad, MD about the caregiver perspective, highlighting the substantial day-to-day...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
